The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials
Open accessAbstract
PURPOSE: Women have more adverse events (AEs) from chemotherapy than men, but few studies have investigated sex differences in immune or targeted therapies. We examined AEs by sex across different treatment domains. METHODS: We analyzed treatment-related AEs by sex in SWOG phase II and III clinical trials conducted between 1980 and 2019, excluding sex-specific cancers. AE codes and grade were categorized using the Common Terminology Criteria for Adverse Events. Symptomatic AEs were defined as those aligned with the National Cancer Institute's Patient-Reported Outcome–Common Terminology Criteria for Adverse Events; laboratory-based or observable/measurable AEs were designated as objective (hematologic v nonhematologic). Multivariable logistic regression was used, adjusting for age, race, and disease prognosis. Thirteen symptomatic and 14 objective AE categories were examined. RESULTS: In total, N = 23,296 patients (women, 8,838 [37.9%]; men, 14,458 [62.1%]) from 202 trials experiencing 274,688 AEs were analyzed; 17,417 received chemotherapy, 2,319 received immunotherapy, and 3,560 received targeted therapy. Overall, 64.6% (n = 15,051) experienced one or more severe (grade ≥ 3) AEs. Women had a 34% increased risk of severe AEs compared with men (odds ratio [OR] = 1.34; 95% CI, 1.27 to 1.42; P < .001), including a 49% increased risk among those receiving immunotherapy (OR = 1.49; 95% CI, 1.24 to 1.78; P < .001). Women experienced an increased risk of severe symptomatic AEs among all treatments, especially immunotherapy (OR = 1.66; 95% CI, 1.37 to 2.01; P < .001). Women receiving chemotherapy or immunotherapy experienced increased severe hematologic AE. No statistically significant sex differences in risk of nonhematologic AEs were found. CONCLUSION: The greater severity of both symptomatic AEs and hematologic AEs in women across multiple treatment modalities indicates that broad-based sex differences exist. This could be due to differences in AE reported, pharmacogenomics of drug metabolism/disposition, total dose received, and/or adherence to therapy. Particularly large sex differences were observed for patients receiving immunotherapy, suggesting that studying AEs from these agents is a priority.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koenker, R., & Bassett, G. (1978) · Econometrica · doi:10.2307/1913643 · Cited by 13,316
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A., & Albain, K. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912303412706 · Cited by 2,174
Self-citationSex Differences in Pharmacokinetics and Pharmacodynamics
Soldin, O. P., & Mattison, D. R. (2009) · Clinical Pharmacokinetics · doi:10.2165/00003088-200948030-00001 · Cited by 1,163
Basch, E., Reeve, B. B., Mitchell, S. A., Clauser, S. B., Minasian, L. M., Dueck, A. C., Mendoza, T. R., Hay, J., Atkinson, T. M., Abernethy, A. P., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju244 · Cited by 1,151
Self-citationCardiovascular Disease in Women: Clinical Perspectives
Garcia, M., Mulvagh, S. L., Bairey Merz, C. N., Buring, J. E., & Manson, J. E. (2016) · Circulation Research · doi:10.1161/circresaha.116.307547 · Cited by 1,080
Considering how biological sex impacts immune responses and COVID-19 outcomes
Scully, E. P., Haverfield, J., Ursin, R. L., Tannenbaum, C., & Klein, S. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0348-8 · Cited by 932
Allikmets, R., Schriml, L. M., Hutchinson, A. A., Romano-Spica, V., & Dean, M. C. (1998) · PubMed · Cited by 918
Insomnia and Risk of Cardiovascular Disease
Javaheri, S., & Redline, S. (2017) · Chest · doi:10.1016/j.chest.2017.01.026 · Cited by 714
Patient Characteristics Associated with Medication Adherence
Rolnick, S. J., Pawloski, P. A., Hedblom, B. D., Asche, S. E., & Bruzek, R. J. (2013) · Clinical Medicine & Research · doi:10.3121/cmr.2013.1113 · Cited by 481
Sex differences in physical symptoms: The contribution of symptom perception theory
van Wijk, C. M. T. G., & Kolk, A. M. (1997) · Social Science & Medicine · doi:10.1016/s0277-9536(96)00340-1 · Cited by 471
Sleep Irregularity and Risk of Cardiovascular Events
Huang, T., Mariani, S., & Redline, S. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.054 · Cited by 363
ROLE OF ABCG2/BCRP IN BIOLOGY AND MEDICINE
Krishnamurthy, P., & Schuetz, J. D. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141238 · Cited by 356
Chapter 1 Gender Differences in Pharmacological Response
Anderson, G. D. (2008) · International Review of Neurobiology · doi:10.1016/s0074-7742(08)00001-9 · Cited by 347
Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients
Yuan, Y., Liu, L., Chen, H., Wang, Y., Xu, Y., Mao, H., Li, J., Mills, G. B., Shu, Y., Li, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.001 · Cited by 331
Sex Differences in Cancer: Epidemiology, Genetics and Therapy
Kim, H.-I., Lim, H., & Moon, A. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.103 · Cited by 315
Women Experience Greater Toxicity With Fluorouracil-Based Chemotherapy for Colorectal Cancer
Sloan, J. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1491 · Cited by 262
Influence of sex and age on fluorouracil clearance.
Milano, G., Etienne, M. C., Cassuto-Viguier, E., Thyss, A., Santini, J., Frenay, M., Renee, N., Schneider, M., & Demard, F. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1171 · Cited by 260
The impact of sex and gender on immunotherapy outcomes
Klein, S. L., & Morgan, R. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00301-y · Cited by 213
Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation
Unger, J. M., Hershman, D. L., Fleury, M. E., & Vaidya, R. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5953 · Cited by 181
Self-citationMerino, G., van Herwaarden, A. E., Wagenaar, E., Jonker, J. W., & Schinkel, A. H. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.011080 · Cited by 178
Consideration of Sex Differences in Medicine to Improve Health Care and Patient Outcomes
Legato, M. J., Johnson, P. A., & Manson, J. E. (2016) · JAMA · doi:10.1001/jama.2016.13995 · Cited by 176
Delbaldo, C., Chatelut, E., Ré, M., Deroussent, A., Séronie-Vivien, S., Jambu, A., Berthaud, P., Le Cesne, A., Blay, J.-Y., & Vassal, G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2596 · Cited by 162
Özdemir, B. C., Csajka, C., Dotto, G. P., & Wagner, D. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3290 · Cited by 153
Chansky, K., Benedetti, J., & Macdonald, J. S. (2005) · Cancer · doi:10.1002/cncr.20878 · Cited by 150
Wakelee, H. A., Wang, W. T., Schiller, J. H., Langer, C. J., Sandler, A. B., Belani, C. P., & Johnson, D. H. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31609-9 · Cited by 146
Normal tissue effects: reporting and analysis
Bentzen, S. M., Dörr, W., Anscher, M. S., Denham, J. W., Hauer‐Jensen, M., Marks, L. B., & WILLIAMS, J. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00036-5 · Cited by 145
Influence of Sex on Toxicity and Treatment Outcome in Small-Cell Lung Cancer
Singh, S., Parulekar, W. R., Murray, N., Feld, R. D., Evans, W. K., Tu, D., & Shepherd, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.171 · Cited by 141
Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry
Dobbs, N. A., Twelves, C. J., Gillies, H., James, C. A., Harper, P., & Rubens, R. D. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685796 · Cited by 117
Han, M. K., Arteaga‐Solis, E., Blenis, J., Bourjeily, G. R., Clegg, D. J., DeMeo, D. L., Duffy, J. F., Gaston, B., Heller, N. M., Hemnes, A. R., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201801-0168ws · Cited by 106
Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity
Meiners, B., Shenoy, C., & Zordoky, B. N. M. (2018) · Biology of Sex Differences · doi:10.1186/s13293-018-0198-2 · Cited by 84
Relative Importance of Dose, Body Surface Area, Sex, and Age for 5-Fluorouracil Clearance
Port, R. E., Daniel, B., Ding, R. W., & Herrmann, R. (2009) · Oncology · doi:10.1159/000226942 · Cited by 67
Davidson, M., Wagner, D., Kouvelakis, K., Nanji, H., Starling, N., Chau, I., Watkins, D. J., Rao, S., Peckitt, C., & Cunningham, D. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.010 · Cited by 65
Sex-related variations in the frequency and characteristics of adverse drug reactions.
Domecq, C., Ca, N., Ruiz, I. C., & Busto, U. (1980) · PubMed · Cited by 64
Zhang, W., Press, O. A., Haiman, C. A., Yang, D., Gordon, M. A., Fazzone, W., El-Khoueiry, A. B., Iqbal, S., Sherrod, A. E., Lurje, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.4710 · Cited by 61
Griggs, J. J., Mangu, P. B., Temin, S., & Lyman, G. H. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2012.000623 · Cited by 61
Pharmacogenomics of Sex Difference in Chemotherapeutic Toxicity
Wang, J., & Huang, Y. S. (2007) · Current Drug Discovery Technologies · doi:10.2174/157016307781115485 · Cited by 55
Sha, J., Qie, G., Yao, Q., Sun, W., Wang, C., Zhang, Z., Wang, X., Wang, P., Jiang, J., Bai, X., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.607059 · Cited by 53
Athauda, A., Nankivell, M. G., Langley, R. E., Alderson, D., Allum, W., Grabsch, H. I., Starling, N., Chau, I., & Cunningham, D. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.005 · Cited by 46
Sharma, R., Cunningham, D., Smith, P., Robertson, G. R., Dent, O. F., & Clarke, S. J. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-153 · Cited by 33
Hu, O. Y., Chang, S.-P., Jame, J.-M., & Chen, K.-Y. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00304769 · Cited by 31
Palma-Gudiel, H., Peralta, V., Deuschle, M., Navarro, V., & Fañanás, L. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.09.002 · Cited by 28
Sex Differences in Efficacy and Toxicity of Systemic Cancer Treatments: Role of the Microbiome
Pala, L., Nezi, L., Pas, T. M. D., Pennacchioli, E., Cocorocchio, E., Ferrucci, P. F., Conforti, F., & Goldhirsch, A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01270 · Cited by 21
Cited by
Evaluation and Mitigation of Racial Bias in Clinical Machine Learning Models: Scoping Review
Huang, J., Galal, G., Etemadi, M., & Vaidyanathan, M. (2022) · JMIR Medical Informatics · doi:10.2196/36388 · Cited by 186
“Bias and disparities along dimensions of race, age, and gender have been shown to impact health care access and delivery, evident in varied settings, such as race correction in clinical algorithms or clinical trial enrollment and adverse event monitoring [16,17].”
The problem with one-size-fits-all medicine: biological sex and the aging immune system
Baker, C., Ansere, V. A., Sanqui, C. I., & Benayoun, B. A. (2026) · PLOS Biology · doi:10.1371/journal.pbio.3003763 · Cited by 3
“Consistently, females receiving immunotherapy had a 49% higher risk of severe adverse events [106].”
Metadata
- Authors
- Unger, J. M., Vaidya, R., Albain, K. S., LeBlanc, M., Minasian, L. M., Gotay, C. C., Henry, N. L., Fisch, M. J., Lee, S. M., Blanke, C. D., & Hershman, D. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-05-01
- Volume
- 40
- Issue
- 13
- Pages
- 1474-1486
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4210620015
- Cited by
- 320
- References
- 42
- FWCI
- 51.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.